Kirin to Release “Slow Drink(R)” Advertisements Promoting Responsible Drinking in Pursuit of Zero Harmful Drinking During the Holiday Season
10.12.2019 12:30:00 EET | Business Wire | Press release
Kirin Holdings Company, Limited (TOKYO:2503) (President and CEO: Yoshinori Isozaki) plans to begin running advertisements promoting responsible drinking on Twitter (Japanese version) starting Friday, December 6, ahead of the peak season for New Year gatherings. The aim of the ads is to prevent the binge drinking, speed drinking, and other dangerous modes of consuming alcohol often observed at these events, and to promote and encourage responsible drinking.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191210005439/en/
IMAGE(1) (Graphic: Business Wire)
The Company unveiled the Kirin Group CSV1 Purpose, which provides guidelines for creating shared value with society and promoting sustainable growth, and serves as long-term, non-financial targets incorporated into the Kirin Group Vision 2027, which represents the Group’s long-term management vision.
The ad campaign is part of our efforts to play a leading role as a responsible alcohol producer as called for in the CSV Purpose.
1CSV: Creating Shared Value. The premise is about creating value that can be shared with customers and society.
The number of people transported emergently to hospitals for acute alcohol poisoning is increasing each year;2 roughly half of those people are in their 20s. The advertisements emphasize the life-threatening danger of binge drinking and other harmful modes of consuming alcohol, and promote responsible drinking namely to people in their 20s who have little experience with alcohol. The ads also communicate the importance of responsible drinking to fulfill the Company’s social responsibility as a manufacturer and seller of alcoholic beverages.
2According to investigations by the fire departments of Tokyo, Osaka, and Nagoya
The Company also plans to stream subtitled English versions of the advertisements with the aim of sharing the message with the world to address the global social issue of harmful alcohol consumption.
YouTube release of subtitled English version: Link: https://youtu.be/0ORj-ZxJdGs
Title: SLOW DRINK (I was just going a little too fast) English version
The Company is proposing “Slow Drink(R)” as a new method of drinking in which people take a relaxed approach to consuming alcohol: being smart and keeping the situation pleasant by drinking in moderation while enjoying good food and conversation with others.
We have created an official logo for “Slow Drink(R)”, and intend to promote new values for alcohol as part of the public education campaign for responsible drinking we are undertaking as an alcohol producer.
In the business environment in which the Kirin Group operates, companies are under increasing pressure to tackle social issues, which include health problems caused by harmful drinking.
We are committed to promoting zero harmful drinking and ensuring that people will continue to enjoy a responsible drinking culture for generations to come.
The Kirin Group is committed to its role as a responsible alcohol producer and addressing the three key social issues: “health and well-being,” “community engagement,” and “the environment.” By fulfilling these commitments, the Group can bring joy to society and a brighter future to our customers.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191210005439/en/
Contact information
For press inquiries, contact:
Corporate Communications Department, Kirin Holdings Co., Ltd.
Tel +81-3-6837-7028
For consumer inquiries, call:
Customer Service, Kirin Holdings Co., Ltd. at 0120-770-502 (toll-free if called from within Japan)
Email address: izawa@ccpr.jp (Ryo Izawa)
Kirin Website: https://www.kirin.co.jp (Images available for download)
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
